Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 4/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121829 | 0.83 | MRGPRX4 (0.37) | HTR4CA14MRGPRX4ALDH1A1KAT8 | |
| SCHEMBL4134605 | 0.78 | MRGPRX4 (0.41) | MRGPRX4ALDH1A1CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL14969145 | 0.70 | HTR2C (0.43) | MRGPRX4ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL15808726 | 0.70 | MRGPRX4 (0.45) | MRGPRX4ALDH1A1CYP4F2CYP4A11KAT8 | |
| SCHEMBL29927275 | 0.69 | CA14 (0.42) | CA14HDAC1HDAC2L3MBTL1 | |
| SCHEMBL4134602 | 0.68 | L3MBTL1 (0.45) | MRGPRX4ALDH1A1CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL7138314 | 0.67 | POLB (0.54) | SIGMAR1L3MBTL1 | |
| SCHEMBL1671124 | 0.67 | TSHR (0.55) | MRGPRX4HDAC1L3MBTL1 | |
| SCHEMBL27412143 | 0.66 | ALDH1A1 (0.41) | ALDH1A1ADRB3 | |
| SCHEMBL18147237 | 0.66 | ALDH1A1 (0.44) | ALDH1A1KAT8L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | disclosed |
| EP-1862451-A1 | Adamantane derivatives for the treatment of inflammatory diseases | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| US-7297818-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2007-11-20 | — | — | US | disclosed |
| US-7132457-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-6881754-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-19 | — | — | US | disclosed |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA AB | 2005-03-03 | — | — | US | disclosed |
| EP-1242364-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1352897-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013704-A1 | Adamantane derivatives | ADRA2C, CHRNA2, ADRA1D | HTR4 1088/4885CA14 1549/4885MRGPRX4 2622/4885 |
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | HTR4 1652/4885CA14 1095/4885MRGPRX4 2407/4885 |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | HRH1, HRH2, HRH4 | HTR4 621/4885CA14 2699/4885MRGPRX4 2308/4885 |
| US-20080139636-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | HTR4 1652/4885CA14 1095/4885MRGPRX4 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.